Publications scientifiques en 2011

Depuis le 31/03/2025
  1. Anti-inflammatory, immunomodulatory, and heme oxygenase-1 inhibitory activities of ravan napas, a formulation of uighur traditional medicine, in a rat model of allergic asthma.
    Abdureyim S, Amat N, Umar A, Upur H, Berke B, Moore N.
    Evid Based Complement Alternat Med. 2011
  2. Treatment of high fat diet induced type 2 diabetes in C57BL/6J mice by two medicinal plants used in traditional treatment of diabetes in the east of Algeria.
    Hamza N, Berke B, Cheze C, Le Garrec R, Lassalle R, Agli AN, Robinson P, Gin H, Moore N.
    J Ethnopharmacol. 2011
  3. The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year.
    Droz-Perroteau C, Dureau-Pournin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A, EULEV Study Group.
    Br J Clin Pharmacol. 2011
  4. Relationship between antibiotic consumption and antibiotic policy: an adjusted analysis in the French healthcare system.
    Amadeo B, Dumartin C, Parneix P, Fourrier-Réglat A, Rogues AM.
    J Antimicrob Chemother. 2011
  5. Who seeks primary care for musculoskeletal disorders (MSDs) with physicians prescribing homeopathic and other complementary medicine? Results from the EPI3-LASER survey in France.
    Rossignol M, Bégaud B, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L.
    BMC Musculoskelet Disord. 2011
  6. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome.
    Saint-Marcoux F, Guigonis V, Decramer S, Gandia P, Ranchin B, Parant F, Bessenay L, Libert F, Harambat J, Bouchet S, Broux F, Compagnon P, Marquet P.
    Pharmacol Res. 2011
  7. Control maintenance can be predicted by exhaled NO monitoring in asthmatic patients.
    Ozier A, Girodet PO, Bara I, Tunon de Lara JM, Marthan R, Berger P.
    Respir Med. 2011
  8. Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention.
    Girodet PO, Ozier A, Bara I, Tunon de Lara JM, Marthan R, Berger P.
    Pharmacol Ther. 2011
  9. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
    Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, Titier K, Molimard M.
    Clin Chim Acta. 2011
  10. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
    Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D.
    Blood. 2011
  11. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents.
    Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, Mallaret M, Lagarde E, CESIR Research Group.
    Clin Pharmacol Ther. 2011
  12. Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort.
    Gulmez SE, Droz-Perroteau C, Lassalle R, Blin P, Bégaud B, Rossignol M, Moore N, Fourrier-Réglat A, CADEUS study group.
    Eur J Clin Pharmacol. 2011
  13. Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors.
    Trent J, Molimard M.
    Semin Oncol. 2011
  14. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study.
    Burbaud P, Ducerf C, Cugy E, Dubos JL, Muller F, Guehl D, Dehail P, Cugy D, Moore N, Lagueny A, Joseph PA.
    J Neurol. 2011
  15. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals.
    Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, Galinier M, Pourrat J, Montastruc JL.
    Pharmacoepidemiol Drug Saf. 2011
  16. Factors associated with the prevalence of antibiotic use for the treatment of hospital-acquired infections at 393 French hospitals: a regional variation analysis.
    Amadeo B, Dumartin C, Venier AG, Fourrier-Réglat A, Coignard B, Rogues AM.
    Infect Control Hosp Epidemiol. 2011
  17. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials.
    Salvo F, Fourrier-Réglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A, Investigators of Safety of Non-Steroidal Anti-Inflammatory Drugs: SOS Project.
    Clin Pharmacol Ther. 2011
  18. Benchmarking clinical management of spinal and non-spinal disorders using quality of life: results from the EPI3-LASER survey in primary care.
    Rossignol M, Bégaud B, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L.
    Eur Spine J. 2011
  19. Journal's withdrawal of article. Paper OK, title wrong.
    Moore N.
    BMJ. 2011
  20. Physiopathologie de l'asthme.
    Ozier A, Bara I, Girodet PO, Marthan R, Berger P.
    Rev Prat. 2011
  21. Relevance of a "Dear Doctor letter" to alert healthcare providers to new recommendations for vitamin D administration.
    Théophile H, Miremont-Salamé G, Robinson P, Moore N, Bégaud B, Haramburu F.
    Eur J Clin Pharmacol. 2011
  22. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.
    Théophile H, Schaeverbeke T, Miremont-Salamé G, Abouelfath A, Kahn V, Haramburu F, Bégaud B.
    Drug Saf. 2011
  23. Use of principal component analysis in the evaluation of adherence to statin treatment: a method to determine a potential target population for public health intervention.
    Latry P, Martin-Latry K, Labat A, Molimard M, Peter C.
    Fundam Clin Pharmacol. 2011
  24. Suicide with cisatracurium and thiopental: forensic and analytical aspects.
    Castaing N, Benali L, Ducint D, Molimard M, Gromb S, Titier K.
    J Anal Toxicol. 2011
  25. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study.
    Latry P, Molimard M, Dedieu B, Couffinhal T, Bégaud B, Martin-Latry K.
    BMC Cardiovasc Disord. 2011
  26. Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, III.
    Bamberger M, Moore N, Lechat P, les participants à la Table Ronde N° 3 de Giens XXVI.
    Therapie. 2011
  27. How to Improve the Clinical Development Paradigm and its Division into Phases I, II and III.
    Bamberger M, Moore N, Lechat P, the participants of Round Table N° 3 of Giens XXVI.
    Therapie. 2011
  28. Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.
    Thiery-Vuillemin A, Montange D, Kalbacher E, Maurina T, Nguyen T, Royer B, Bouchet S, Bazan F, Curtit E, Pivot X.
    Ann Oncol. 2011
  29. The case-population study design: an analysis of its application in pharmacovigilance.
    Théophile H, Laporte JR, Moore N, Martin KL, Bégaud B.
    Drug Saf. 2011
  30. Engagement in leisure activities and benzodiazepine use in a French community-dwelling elderly population.
    Bazin F, Noize P, Dartigues JF, Ritchie KA, Tavernier B, Moore N, Pariente A, Fourrier-Reglat A.
    Int J Geriatr Psychiatry. 2011
  31. Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment.
    Riedel M, Lafitte M, Pucheu Y, Latry K, Couffinhal T.
    Eur J Cardiovasc Prev Rehabil. 2011